Back to top
more

Trevena (TRVN)

(Delayed Data from NSDQ)

$0.24 USD

0.24
482,045

+0.01 (5.75%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $0.24 0.00 (-0.46%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat

by Zacks Equity Research

Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.

Geron (GERN) Soars on Imetelstat Data for Myelofibrosis

by Zacks Equity Research

Geron (GERN) publishes data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory myelofibrosis. Stock rises.

All You Need to Know About Trevena (TRVN) Rating Upgrade to Buy

by Zacks Equity Research

Trevena (TRVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Moving Average Crossover Alert: Trevena (TRVN)

by Zacks Equity Research

Trevena (TRVN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Trevena (TRVN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Trevena (TRVN) will provide updates on its newly launched drug and other pipeline products when it releases its third-quarter 2020 results.

Has Trevena (TRVN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (TRVN) Outperforming Other Medical Stocks This Year?

Trevena's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Trevena.

Is the Options Market Predicting a Spike in Trevena (TRVN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.

Implied Volatility Surging for Trevena (TRVN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Trevena (TRVN) stock based on the movements in the options market lately.

Trevena (TRVN) Looks Good: Stock Adds 8.8% in Session

by Zacks Equity Research

Trevena (TRVN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Company News for June 3, 2020

by Zacks Equity Research

Companies in the news are: DCI, TENX, TRVN, BHTG

Is Trevena (TRVN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (TRVN) Outperforming Other Medical Stocks This Year?

Has Trevena, Inc. (TRVN) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (TRVN) Outperforming Other Medical Stocks This Year?

Seattle Genetics Gets Early FDA Nod for Breast Cancer Drug

by Zacks Equity Research

The FDA grants accelerated nod to Seattle Genetics' (SGEN) Tukysa in combination with Herceptin and Xeloda to treat adults with advanced unresectable metastatic HER2-positive breast cancer.

Trevena Enters Oversold Territory

by Zacks Equity Research

Trevena has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Axsome's (AXSM) AXS-05 Fails to Meet Main Goal in TRD Study

by Zacks Equity Research

Axsome's (AXSM) AXS-05 meets key secondary endpoints in late-stage study for addressing patients with treatment resistant depression. However, the primary endpoint did not reach statistical significance.

Trevena's NDA for Pain Drug Oliceridine Gets FDA Acceptance

by Zacks Equity Research

FDA accepts Trevena's (TRVN) NDA for opioid analgesic, oliceridine, re-submitted last month. A decision is expected in August.

Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA

by Zacks Equity Research

Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.

FDA Grants Priority Review to Global Blood's SCD Candidate

by Zacks Equity Research

The FDA accepts Global Blood's (GBT) new drug application for voxelotor under priority review to treat sickle cell disease. A decision is expected on Feb 26, 2020.

Trevena Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Trevena has been struggling lately, but the selling pressure may be coming to an end soon.

Emergent's Vaccine Portfolio Aids Growth Amid Competition

by Zacks Equity Research

Emergent's (EBS) vaccine portfolio holds potential with the newly-acquired Narcan nasal spray performing well in the first half of 2019. Stiff competition is a lingering concern.

Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?

by Zacks Equity Research

During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.

Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study

by Zacks Equity Research

Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.

Trevena (TRVN) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Trevena (TRVN) closed at $1.70 in the latest trading session, marking a +1.19% move from the prior day.

Will Trevena Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Trevena.